Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
Table 4
Univariate analysis of overall survival.
Variable
n
OR [95% CI]
value
Clinical data
Breslow index (mm)
10
1.13 [0.7514–1.718]
0.545
PS > 0
10
3.448 [0.67–17.6]
0.137
LDH > N
10
1.3 [0.32–5.4]
0.716
AJCC stage IV
10
0.81 [0.198–3.28]
0.763
Metastatic disease diagnosis to TIL infusion (years)
10
1.01 [0.835–1.23]
0.887
Ipilimumab before TILs
10
1.1 [0.26–4.57]
0.913
Ipilimumab after TILs
10
0.59 [0.12–2.98]
0.526
TILs infused (×109)
10
1.04 [0.94–1.16]
0.449
BRAF mutation V600E
9
0.38 [0.07–2.03]
0.260
c-KIT mutated
10
3.97 [0.36–43.9]
0.261
Melanoma cell PCR
MAGE-1
7
0.41 [0.04–4.68]
0.476
MAGE-3
7
1.04 [0.11–9.66]
0.503
Melan-A
7
17.5 [0.21–1483]
0.207
NY-ESO-1
6
NA
0.999
Na17A
7
9.58 [0.22–411]
0.239
gp100
7
0.86 [0.04–16.8]
0.923
Tyrosinase
7
NA
0.998
TIL phenotypes
CD3+
9
NA
0.643
CD3 + CD4+
9
3.15 [0.28–35.6]
0.355
CD3 + CD8+
9
4.78 [0.14–166]
0.388
CD4 + CD25+
9
NA
0.071
CD4 + CD25 + CD127lowCTLA4+
9
0.97 [0.02–57.97]
0.987
CD4 + CD25 + CD127lowFoxp3+
9
16E7 [43.4–6E12]
0.011
AJCC: American Joint Committee on Cancer; CI: confidence interval; LDH: lactate dehydrogenase; MAGE-1 and -3: melanoma antigen-1 and -3; NA: data not available; NY-ESO1: New York esophageal squamous cell carcinoma 1; PS: performance status. Significant value.
